Resistance to Mupirocin: No Indication of it to Date While Using Mupirocin Ointment for Prevention of Staphylococcus Aureus Exit-Site Infections in Peritoneal Dialysis Patients
Restricted accessResearch articleFirst published online July, 1999
Resistance to Mupirocin: No Indication of it to Date While Using Mupirocin Ointment for Prevention of Staphylococcus Aureus Exit-Site Infections in Peritoneal Dialysis Patients
PirainoB.A review of Staphylococcus aureus exit-site and tunnel infections in peritoneal dialysis patients.Am J Kidney Dis1990; 16: 89–95.
2.
SheltonD.M.A comparison of the effects of two antiseptic agents on Staphylococcus epidermidis colony forming units at the peritoneal dialysis catheter exit site. In: KhannaR., NolphK.D., ProwantB. F., TwardowskiZ.J., OreopoulosD.G., eds. Advances in peritoneal dialysis.Toronto: Peritoneal Dialysis Bulletin, 1991; 7: 120–4.
3.
WilsonA.P., LewisC., O'SullivanH., ShettyN., NeildG.H., MansellM.The use of povidone iodine in exit site care for patients undergoing continuous peritoneal dialysis (CAPD).J Hosp Infect1997; 35: 287–93.
4.
ZimmermanS.W., AhrensE., JohnsonC.A., CraigW., LeggetJ., O'BrienM.Randomized controlled trial of prophylactic rifampin for peritoneal dialysis-related infections.Am J Kidney Dis1991; 18: 225–31.
5.
BoyceJ.M.Preventing staphylococcal infections by eradicating nasal carriage of Staphylococcus aureus: proceeding with caution.Infect Control Hosp Epidemiol1996; 17: 775–9.
6.
Perez-FontanM., Garcia-FalconT., RosalesM., Rodriguez-CarmonaA., AdevaM., Rodriguez-LozanoI.Treatment of Staphylococcus aureus nasal carriers in continuous ambulatory peritoneal dialysis with mupirocin: long term results.Am J Kidney Dis1993; 22: 708–12.
7.
Mupirocin Study Group. Nasal mupirocin prevents Staphylococcus aureus exit-site infection during peritoneal dialysis.J Am Soc Nephrol1996; 7: 2403–8.
8.
BernardiniJ., PirainoB., HolleyJ., JohnstonJ.R., LutesR.A randomized trial of Staphylococcus aureus prophylaxis in peritoneal dialysis patients: mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin.Am J Kidney Dis1996; 27: 695–700.
9.
ThodisE., BhaskaranS., PasadakisP., BargmanJ.M., VasS.I., OreopoulosD.G.Decrease in Staphylococcus aureus exit-site infections and peritonitis in CAPD patients by local application of mupirocin ointment at the catheter exit site.Perit Dial Int1998; 18: 261–70.
10.
MillerM.A., DascalA., PortnoyJ., MendelsonJ.Development of mupirocin resistance among methicillin resistant Staphylococcus aureus after widespread use of nasal mupirocin ointment.Infect Control Hosp Epidemiol1996; 17: 811–13.
11.
FongS.K., DedierH., IzattS., VasS., OreopoulosD.G., CampbellE.The lack of colonization of methicillin resistant S. aureus, mupirocin resistant S. aureus and vancomycin intermediate resistant S. aureus in a chronic ambulatory dialysis population.Can J Infect Dis1998; 9(Suppl D): 32D.
